Home » Stocks » Sutro Biopharma

Sutro Biopharma, Inc. (STRO)

Stock Price: $12.64 USD 0.59 (4.90%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed
After-hours: $12.75 +0.11 (0.87%) Oct 22, 4:13 PM

Stock Price Chart

Key Info

Market Cap 453.51M
Revenue (ttm) 40.20M
Net Income (ttm) -17.42M
Shares Out 35.88M
EPS (ttm) -0.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 22, 2020
Last Price $12.64
Previous Close $12.05
Change ($) 0.59
Change (%) 4.90%
Day's Open 12.04
Day's Range 12.04 - 12.79
Day's Volume 75,767
52-Week Range 6.00 - 13.91

More Stats

Market Cap 453.51M
Enterprise Value 227.32M
Earnings Date (est) Nov 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 35.88M
Float 23.77M
EPS (basic) -1.04
EPS (diluted) -0.71
FCF / Share -2.83
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.68M
Short Ratio 4.15
Short % of Float 11.29%
Beta 0.58
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 11.28
PB Ratio 2.07
Revenue 40.20M
Operating Income -63.11M
Net Income -17.42M
Free Cash Flow -65.76M
Net Cash 226.19M
Net Cash / Share 6.30
Gross Margin -56.90%
Operating Margin -156.99%
Profit Margin -43.30%
FCF Margin -163.56%
ROA -17.49%
ROE -10.68%
ROIC -8.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 7
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$19.83*
(56.88% upside)
Low
16.0
Current: $12.64
High
23.0
Target: 19.83
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016
Revenue42.7438.4251.7459.73
Revenue Growth11.24%-25.75%-13.38%-
Gross Profit42.7438.4251.7459.73
Operating Income-55.47-37.22-19.271.36
Net Income-55.74-35.32-19.691.70
Shares Outstanding22.965.760.450.41
Earnings Per Share-2.43-6.13-43.95-
Operating Cash Flow-65.0212.68-37.07-13.15
Capital Expenditures-3.48-1.56-3.32-4.38
Free Cash Flow-68.5011.13-40.39-17.53
Cash & Equivalents11820522.0447.80
Total Debt9.8814.7214.56-
Net Cash / Debt1081907.4747.80
Assets15622340.7769.28
Liabilities58.5891.6047.2757.67
Book Value97.79132-109-90.90
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Sutro Biopharma, Inc.
Country United States
Employees 177
CEO William J. Newell

Stock Information

Ticker Symbol STRO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: STRO
IPO Date September 27, 2018

Description

Sutro Biopharma operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.